Highlights from the annual meeting of the National Leiomyosarcoma Foundation
Javier Martin-Broto, Sarcoma Medical Oncologist at the University Hospital Fundacion Jimenez Diaz, shared a post on LinkedIn:
“On September 27th and 28th, the annual meeting of the National Leiomyosarcoma Foundation (NLMSF) is being held at Princess Margaret Hospital in Toronto. Hosted by Albiruni Razak and with the tireless efforts of Rebecca Gladdy, Jasmine Lee, and Michel Achee, among many others, this event brings promising news for leiomyosarcoma patients.
One highlight is the significantly prolonged progression-free survival (1 year) in the first line of treatment with the combination of Doxorubicin and Trabectedin, as reported by the French group led by Patricia Pautier and recently published in NEJM.
Additionally, there is an impressive 56.5% response rate observed with the combination of Doxorubicin+DTIC and Nivolumab in the first line of advanced disease, based on mature data from a study that will soon be published in JCO.
A heartfelt thanks to NLMSF for their relentless energy in continuing to research LMS, aiming to develop new and effective treatments for our patients.”
Source: Javier Martin-Broto/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023